Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

17

Revenue 2017

Stelara

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Stelara was produced by Johnson & Johnson.

J&J inks $6.5bn all-cash deal to acquire Momenta

J&J inks $6.5bn all-cash deal to acquire Momenta

J&J already has high stakes in the autoimmune disease market, with some of its existing products, including psoriasis med Stelara (ustekinumab), already reaching blockbuster status.

J&J splashes $750m on anti-inflammatory drug bermekimab

J&J splashes $750m on anti-inflammatory drug bermekimab J&J already has high stakes in the anti-inflammatory market, with its blockbuster IL-12/IL-23 inhibitor blockbuster Stelara (ustekinumab) and follow-up Tremfya (guselkumab). ... The therapy is a follow-up to its older blockbuster Stelara, which is facing

UCB’s bimekizumab beats AbbVie’s Humira in phase 3 trial

UCB’s bimekizumab beats AbbVie’s Humira in phase 3 trial This includes a recent phase 3 BE VIVID study comparing the drug to Johnson &Johnson’s Stelara (ustekinumab), which bimekizumab also demonstrated superiority over.

Janssen files Tremfya for psoriatic arthritis in Europe

Janssen files Tremfya for psoriatic arthritis in Europe First approved in Europe two years ago, Tremfya (guselkumab) is the follow-up to J&J’s IL-12/IL-23 inhibitor blockbuster Stelara (ustekinumab), which is facing increased competition across ... of Stelara – which made $4.66bn in the first three

CHMP says OK to UCB/Amgen’s Evenity for osteoporosis after appeal

CHMP says OK to UCB/Amgen’s Evenity for osteoporosis after appeal showed it was better at clearing skin than placebo and Johnson &Johnson’s big-selling Stelara (ustekinumab) product.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Origins Insights

Our goal is to identify and embed transformational patient insights as a fundamental part of the drug development process. As...

Latest intelligence

Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
News:
Senior Analytics Specialist joins Research Partnership...
Digital technologies: Pharma’s answer to achieving net zero emissions?
...